Efficacy and Safety of First-line Targeted Therapies in Physically Fit Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis
{"title":"Efficacy and Safety of First-line Targeted Therapies in Physically Fit Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis","authors":"Anita Stożek-Tutro MSc , Monika Reczek MPharm , Paweł Kawalec MD, PhD","doi":"10.1016/j.clinthera.2025.01.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Targeted therapies are promising treatment options for fit patients with untreated chronic lymphocytic leukemia (CLL). However, there is a lack of data on their relative efficacy and safety. The aim of this systematic review was to assess the relative efficacy and safety of first-line targeted therapies (including venetoclax [VEN], obinutuzumab [OBI], ibrutinib [IBR], and other options) for physically fit patients with untreated CLL.</div></div><div><h3>Methods</h3><div>A systematic literature review of major medical databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) and additional data sources was conducted to identify randomized controlled trials providing data of interest. Progression-free survival (PFS) and undetectable minimal residual disease (MRD(-)) in peripheral blood (PB) were analyzed, along with other end points. A Bayesian network meta-analysis was used for data analysis. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, and its protocol was registered in the International Prospective Register of Systematic Reviews (CRD42023393903).</div></div><div><h3>Findings</h3><div>The network meta-analysis results reported no significant differences between targeted therapies for PFS. However, IBR + VEN and VEN + OBI + IBR reported the highest probability of being the most effective options based on surface under the cumulative ranking curve values. For MRD(-)PB, VEN + OBI + IBR reported a significant advantage over other therapies, with surface under the cumulative ranking curve values confirming it as the most effective option in this term.</div></div><div><h3>Implications</h3><div>Targeted therapies may offer a promising treatment option for fit patients with previously untreated CLL. Among the therapies assessed, IBR + rituximab and VEN + OBI + IBR emerge as the most effective therapeutic options for prolonging PFS, while VEN + OBI + IBR and VEN + OBI reported favorable outcomes in achieving MRD(-)PB. However, further research is needed to validate these findings.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 5","pages":"Pages e12-e20"},"PeriodicalIF":3.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825000104","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Targeted therapies are promising treatment options for fit patients with untreated chronic lymphocytic leukemia (CLL). However, there is a lack of data on their relative efficacy and safety. The aim of this systematic review was to assess the relative efficacy and safety of first-line targeted therapies (including venetoclax [VEN], obinutuzumab [OBI], ibrutinib [IBR], and other options) for physically fit patients with untreated CLL.
Methods
A systematic literature review of major medical databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) and additional data sources was conducted to identify randomized controlled trials providing data of interest. Progression-free survival (PFS) and undetectable minimal residual disease (MRD(-)) in peripheral blood (PB) were analyzed, along with other end points. A Bayesian network meta-analysis was used for data analysis. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, and its protocol was registered in the International Prospective Register of Systematic Reviews (CRD42023393903).
Findings
The network meta-analysis results reported no significant differences between targeted therapies for PFS. However, IBR + VEN and VEN + OBI + IBR reported the highest probability of being the most effective options based on surface under the cumulative ranking curve values. For MRD(-)PB, VEN + OBI + IBR reported a significant advantage over other therapies, with surface under the cumulative ranking curve values confirming it as the most effective option in this term.
Implications
Targeted therapies may offer a promising treatment option for fit patients with previously untreated CLL. Among the therapies assessed, IBR + rituximab and VEN + OBI + IBR emerge as the most effective therapeutic options for prolonging PFS, while VEN + OBI + IBR and VEN + OBI reported favorable outcomes in achieving MRD(-)PB. However, further research is needed to validate these findings.
期刊介绍：
Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
